Daito Pharmaceutical Co.,Ltd. announced that it expects to receive ¥7.836 million in funding from Daiwa Securities Co., Ltd., Investment Arm
September 05, 2019
Share
Daito Pharmaceutical Co.,Ltd. (TSE:4577) announced a private placement of 12,000 warrants at an issue price of ¥653 per warrant for gross proceeds of ¥7,836,000 with new investor Daiwa Securities Co., Ltd., Investment Arm on September 6, 2019. The warrants are exercisable into common shares at an initial exercise price of ¥3,045 and will receive proceeds of ¥3,661,836,000 post exercise. The warrant exercise period is from September 25, 2019 to September 24, 2021. The transaction has been approved by the board of directors and is expected to close on September 24, 2019. The transaction will take place through third party allotment method.
Daito Pharmaceutical Co., Ltd. is a Japan-based company mainly engaged in the pharmaceutical ingredients and formulation business, as well as healthy food. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.
DAITO PHARMACEUTICAL CO.,LTD. 
